- איגודים
- אונקולוגיה
- אורולוגיה
- טיפול נמרץ
- מומחים צעירים
- מיילדות וגינקולוגיה
- משפחה
- נוירולוגיה
- עור ומין
- המטולוגיה
- חברות
- אורואונקולוגיה
- אם ועובר
- אנדוסקופיה גינקולוגית
- גידולי מערכת העיכול
- גיל המעבר
- החברה להפרעת קשב
- החברה לכאב ראש
- הפרעות תנועה
- טיפול בכאב
- טיפול פליאטיבי
- מחלות מטבוליות
- מלנומה
- סרטן השד
- סרטן ריאות
- רדיותרפיה
- רפואת אורחות חיים
מן הרשת
Meta-Analysis Finds Adding ADT to EBRT Extends Survival in Localized Prostate Cancer
External beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT) showed superior overall survival (OS) compared with EBRT plus a brachytherapy boost (BT) in men with intermediate- and high-risk prostate cancer
Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC
Results from the TheraP trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after treatment with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel
PD-L1 Expression on Tumour-Infiltrating Immune Cells Has No Prognostic Value in Renal Cell Carcinoma
Programmed death ligand 1 (PD-L1) status on tumour-infiltrating immune cells was not an independent prognostic factor for patients with recurrent or metastatic renal cell carcinoma, according to a study presented at the 2020 American Urological Association (AUA) Virtual Meeting
MR-Guided Focused Ultrasound Therapy Is Effective for Grade Group 2, 3 Prostate Cancer
Magnetic resonance-guided focused ultrasound (MRgFUS) focal therapy using real-time MR thermometry is effective for grade group 2 and 3 prostate cancer, according to a study presented at the 2020 American Urological Association (AUA) Virtual Meeting
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
Adding avelumab (Bavencio) to best supportive care (BSC) improved the median overall survival (OS) by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study presented during the 2020 ASCO Virtual Scientific Program
FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression
On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression
FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Rare Form of Lung Cancer
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases
FDA Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
FDA Approves Opdivo-Yervoy Combination For Treatment of Metastatic NSCLC
The Food and Drug Administration has approved the combination of Opdivo-Yervoy immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer that do not have certain genomic tumor aberrations
מחקרים וחדשות רפואה
-
מן הרשת03.06.2021, 16:52
-
טיפול בקרינה03.06.2021, 14:49
-
לוקמיה לימפובלסטית03.06.2021, 14:19
-
תיאור מקרה03.06.2021, 14:08
7 הכי נקראות
-
1
-
2
-
3
-
4
-
5
-
6
-
7
תגובות אחרונות